Remdesivir questioned by WHO trial; women take virus more seriously than men

In a blow to one of the few drugs being used to treat COVID-19, the World Health Organization (WHO) said interim trial results suggest that Gilead's remdesivir was no better than a placebo at limiting severely ill patients' need for mechanical ventilation, the length of their hospital stay, or their risk of death. Then, the authors looked at data on nearly 740,000 COVID-19 patients and examined the use of drugs that work to protect these processes, asking whether patients who received them fared better - and they did, in some cases.